Zafgen Announces Partial Clinical Hold Affecting Beloranib Trials

RBC Capital Sees Attractive Risk/Reward in Zafgen (ZFGN)

RBC Capital analyst Simos Simeonidis lowered his price target on Zafgen (NASDAQ: ZFGN) to $20.00 (from $46.00) but maintained an Outperform rating after the company announced on Friday that FDA has placed beloranib on partial clinical hold given that the recent patient death in the trial was on the drug arm.

Simeonidis said while the news obviously adds significant risk, they believe that ZFGN shares are now at levels that represent attractive risk/reward.

The firm's key points:

Current ZFGN levels assume very low probability of success for the... More

UPDATE: FBR Downgrades Zafgen (ZFGN) to Sector Perform

(Updated - October 16, 2015 3:04 PM EDT)

(Update corrects name of firm to FBR.

FBR downgraded Zafgen (NASDAQ: ZFGN) from Outperform to Sector Perform with a price target of $16.00 (from $48.00). The change follows an announcement related to a partial clinical hold of... More

Cowen Cuts Price Target on Zafgen (ZFGN) as Beloranib is Placed on Hold Following Patient Death

Cowen reiterated an Outperform rating on Zafgen (NASDAQ: ZFGN), and cut the price target to $20.00 (from $60.00), following FDA'a decision to place beloranib on a partial clinical hold. Late yesterday ZFGN received verbal notice from the FDA that beloranib has been placed on partial... More

Zafgen's (ZFGN) Beloranib Placed on Partial Clinical Hold by FDA

Zafgen (NASDAQ: ZFGN) announced that it received verbal notice late yesterday from the U.S. Food and Drug Administration (FDA) that beloranib has been placed on partial clinical hold. This partial clinical hold impacts ongoing or planned clinical trials, including ZAF-311 and ZAF-312. A partial clinical hold is an order that the FDA issues to delay or suspend part of a sponsors clinical work requested under its investigational new drug (IND) application.

As previously reported, Zafgen learned of a death in the ongoing Phase 3 bestPWS study (ZAF-311) of... More